Fig 1: ELISA validation of APOA1, APOC3, Adiponectin and PCSK9 in another cohort. (A) The concentration comparison and (B) ROC analysis of APOA1, APOC3, Adiponectin and PCSK9 between CGE patients and healthy controls.
Fig 2: Model of the mediation of the observed relationship between TMAO and PCSK9 by IL-8. Model adjusted for BMI and ASCVD risk score, (n = 60). ASCVD: atherosclerotic cardiovascular disease; BMI: body mass index; IL: interleukin; TMAO: trimethylamine N-oxide; PCSK9: proprotein convertase subtilisin/kexin type 9. Created with BioRender.com (accessed on 25 February 2022).
Fig 3: (A) Endogenous production of TMAO from dietary precursors. (B) Mechanism of action of PCSK9 in the disruption of LDL receptor recycling. Created with BioRender.com (accessed on 9 November 2022).
Supplier Page from BioLegend for LEGEND MAX(TM) Human PCSK9 ELISA Kit